Works matching AU Thanarajasingam, Gita
Results: 45
SOHO State of the Art Updates and Next Questions | Measuring Patient-Reported Outcomes (PROs) and Treatment Tolerability in Patients With Hematologic Malignancies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2025, v. 25, n. 3, p. 142, doi. 10.1016/j.clml.2024.07.018
- By:
- Publication type:
- Article
Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®).
- Published in:
- Quality of Life Research, 2025, v. 34, n. 2, p. 495, doi. 10.1007/s11136-024-03819-5
- By:
- Publication type:
- Article
The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Optimization of alert notifications in electronic patient-reported outcome (ePRO) remote symptom monitoring systems (AFT-39).
- Published in:
- Quality of Life Research, 2024, v. 33, n. 7, p. 1985, doi. 10.1007/s11136-024-03675-3
- By:
- Publication type:
- Article
Correction to: Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2.
- Published in:
- Quality of Life Research, 2022, v. 31, n. 4, p. 1069, doi. 10.1007/s11136-021-02968-1
- By:
- Publication type:
- Article
IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S401, doi. 10.1016/S2152-2650(21)01906-6
- By:
- Publication type:
- Article
Poster: IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S244, doi. 10.1016/S2152-2650(21)01536-6
- By:
- Publication type:
- Article
Oral Abstract: IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S203, doi. 10.1016/S2152-2650(21)01277-5
- By:
- Publication type:
- Article
Clinical Characteristics and Outcome of Transformed Diffuse Large B-Cell Lymphoma in the Rituximab Era: A SEER Database Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S362, doi. 10.1016/j.clml.2017.07.196
- By:
- Publication type:
- Article
Impact of lymphoma survivorship clinic visit on patient-centered outcomes.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Primary Skull Base Lymphoma: Manifestations and Clinical Outcomes of a Great Imitator.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?
- Published in:
- Nutrition & Cancer, 2018, v. 70, n. 7, p. 1088, doi. 10.1080/01635581.2018.1502328
- By:
- Publication type:
- Article
Event‐free survival at 24 months captures central nervous system relapse of systemic diffuse large B‐cell lymphoma in the immunochemotherapy era.
- Published in:
- British Journal of Haematology, 2018, v. 183, n. 1, p. 149, doi. 10.1111/bjh.14922
- By:
- Publication type:
- Article
Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 1, p. 50, doi. 10.1111/bjh.14813
- By:
- Publication type:
- Article
Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 658, doi. 10.1002/hon.2919
- By:
- Publication type:
- Article
Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance).
- Published in:
- Cancer (0008543X), 2014, v. 120, n. 22, p. 3575, doi. 10.1002/cncr.28892
- By:
- Publication type:
- Article
Immune checkpoint blockade in lymphoid malignancies.
- Published in:
- FEBS Journal, 2016, v. 283, n. 12, p. 2233, doi. 10.1111/febs.13668
- By:
- Publication type:
- Article
Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials.
- Published in:
- 2023
- By:
- Publication type:
- journal article
Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real‐world patients.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 4, p. 661, doi. 10.1111/bjh.16425
- By:
- Publication type:
- Article
Accessory splenectomy for refractory immune thrombocytopenic purpura.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 6, p. 520, doi. 10.1002/ajh.22011
- By:
- Publication type:
- Article
Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance.
- Published in:
- European Journal of Haematology, 2009, v. 83, n. 1, p. 17, doi. 10.1111/j.1600-0609.2009.01246.x
- By:
- Publication type:
- Article
PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Capturing and Incorporating Patient-Reported Outcomes into Clinical Trials: Practical Considerations for Clinicians.
- Published in:
- Current Oncology Reports, 2016, v. 18, n. 10, p. 1, doi. 10.1007/s11912-016-0549-2
- By:
- Publication type:
- Article
Parental health in fellowship trainees: Fellows' satisfaction with current policies and interest in innovation.
- Published in:
- Women's Health (17455057), 2020, p. 1, doi. 10.1177/1745506520949417
- By:
- Publication type:
- Article
Parental health in fellowship trainees: Fellows' satisfaction with current policies and interest in innovation.
- Published in:
- Women's Health (17455057), 2020, v. 16, p. 1, doi. 10.1177/1745506520949417
- By:
- Publication type:
- Article
Wearable sensor-based performance status assessment in cancer: A pilot multicenter study from the Alliance for Clinical Trials in Oncology (A19_Pilot2).
- Published in:
- PLoS Digital Health, 2023, v. 1, n. 1, p. 1, doi. 10.1371/journal.pdig.0000178
- By:
- Publication type:
- Article
Critical gaps in understanding treatment outcomes in adolescents and young adults with lymphoma: A review of current data.
- Published in:
- EJHaem, 2023, v. 4, n. 4, p. 927, doi. 10.1002/jha2.778
- By:
- Publication type:
- Article
Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer.
- Published in:
- Case Reports in Oncological Medicine, 2015, v. 2015, p. 1, doi. 10.1155/2015/420159
- By:
- Publication type:
- Article
Central nervous system involvement by mantle cell lymphoma.
- Published in:
- Leukemia & Lymphoma, 2023, v. 64, n. 2, p. 371, doi. 10.1080/10428194.2022.2148211
- By:
- Publication type:
- Article
The association of health behaviors with quality of life in lymphoma survivors.
- Published in:
- Leukemia & Lymphoma, 2021, v. 62, n. 2, p. 271, doi. 10.1080/10428194.2020.1830389
- By:
- Publication type:
- Article
Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Predictors of short-term survival in Waldenström Macroglobulinemia.
- Published in:
- 2020
- By:
- Publication type:
- Letter
Efficacy, safety, and dose adjustment of cyclophosphamide in lymphoma patients requiring hemodialysis.
- Published in:
- Leukemia & Lymphoma, 2017, v. 58, n. 2, p. 457, doi. 10.1080/10428194.2016.1190977
- By:
- Publication type:
- Article
Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non‐Small Cell Lung Cancer in CALGB 9730 (Alliance A151729).
- Published in:
- Oncologist, 2021, v. 26, n. 3, p. e435, doi. 10.1002/onco.13527
- By:
- Publication type:
- Article
Fluorodeoxyglucose‐Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma.
- Published in:
- Oncologist, 2020, v. 25, n. 8, p. 689, doi. 10.1634/theoncologist.2019-0952
- By:
- Publication type:
- Article
Estrogen enhances light-induced activation of dorsal raphe serotonergic neurons.
- Published in:
- European Journal of Neuroscience, 2005, v. 21, n. 6, p. 1536, doi. 10.1111/j.1460-9568.2005.03964.x
- By:
- Publication type:
- Article
Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Immune‐related hematologic adverse events in the context of immune checkpoint inhibitor therapy.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 10, p. E362, doi. 10.1002/ajh.26273
- By:
- Publication type:
- Article
Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. 979, doi. 10.1002/ajh.26230
- By:
- Publication type:
- Article
Assessment of fixed‐duration therapies for treatment‐naïve Waldenström macroglobulinemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. 945, doi. 10.1002/ajh.26210
- By:
- Publication type:
- Article
Testicular FDG‐PET/CT uptake threshold in aggressive lymphomas.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 3, p. E81, doi. 10.1002/ajh.26073
- By:
- Publication type:
- Article
Methodological standards for using the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in cancer clinical trials.
- Published in:
- Clinical Trials, 2022, v. 19, n. 3, p. 274, doi. 10.1177/17407745221093922
- By:
- Publication type:
- Article
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
- Published in:
- Clinical Trials, 2021, v. 18, n. 1, p. 104, doi. 10.1177/1740774520975120
- By:
- Publication type:
- Article